Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study

N/ANot Yet RecruitingNCT07161167

Peking Union Medical College Hospital6,743 enrolled

Overview

Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA/CT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat/muscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.

Study Type

OBSERVATIONAL

Enrollment

6,743

Conditions

Obesity Rekated Cancer Body Composition Changes Survival Mechanism

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥18 years, regardless of gender. 2. Histologically or cytologically confirmed obesity-associated malignant tumors (e.g., breast cancer, colorectal cancer, gastric cancer, lung cancer, or thyroid cancer) with planned treatment after diagnosis (any treatment modality permitted). 3. No prior chemotherapy, radiotherapy, biologic therapy, immunotherapy, or other antitumor treatments for malignancy. Exclusion Criteria: 1. Patients with concurrent non-obesity-related malignancies. 2. History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin). 3. Patients with concurrent multiorgan dysfunction syndrome, autoimmune diseases, infectious diseases, neurological disorders, or psychiatric disorders.

Outcomes

Primary Outcomes

Overall survival

The time from the start of follow-up to death (for any reason).

Time frame: From date of diagnosis until the date of death from any cause, assessed up to 10 years

Secondary Outcomes

Progression-free survival after diagnosis

Time frame: From date of diagnosis until the date of first documented progression , assessed up to 10 years

Time of recurrence and/or distant metastasis after diagnosis

Time frame: From date of diagnosis until the date of first documented recurrence and/or distant metastasis, whichever came first, assessed up to 10 years